Quintiles
4
28M
3
0.10
0.25
2
- Areas of investment
Summary
In 1982 was created Quintiles, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Austin. The company was established in North America in United States.
The increased amount of exits for fund were in 2009. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2001.
We can highlight the next thriving fund investment areas, such as Medical, Pharmaceutical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - Israel. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight D Pharm LTD., NitroMed.
The standard case for the fund is to invest in rounds with 8-9 partakers. The meaningful sponsors for the fund in investment in the same round are Rho Ventures, Vertex Ventures Israel, Vertex Ventures.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 0.10
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (4)
- Biopharma (3)
- Pharmaceutical (2)
- Therapeutics (2)
- Medical (1)
- Investments by region
-
- United States (3)
- Israel (1)
- Peak activity year
- 2001
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 28
- Avg. valuation at time of investment
- 110M
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Bayhill Therapeutics | 04 May 2005 | Biotechnology, Therapeutics, Biopharma | Early Stage Venture | 35M | United States, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.